Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KALA BIO, Inc. - Common Stock (NQ:KALA)

16.07 +0.80 (+5.24%)
Streaming Delayed Price Updated: 10:55 AM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KALA BIO, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companies 
From KALA BIO, Inc.
Via GlobeNewswire
5 Healthcare Stocks On Fire This Week
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma. 
Via Benzinga
KALA Stock Earnings: Kala Bio Beats EPS for Q2 2024
KALA stock results show that Kala Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Kala Bio (KALA) Q2 Loss Widens 15%
Via The Motley Fool
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From KALA BIO, Inc.
Via GlobeNewswire
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
From KALA BIO, Inc.
Via GlobeNewswire
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction
Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects. 
Via Stocktwits
Dow Drops More Than 400 Points After CPI Data
This morning's hotter-than-expected CPI data sent the market reeling, after the annual inflation rate rose to 3% and the 12-month core inflation rate rose to 3.3%. 
Via Talk Markets
Topics Economy Stocks Stocks / Equities
KALA BIO Announces Chief Executive Officer Transition
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Announces $10,750,000 Private Placement
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Announces $12,500,000 Private Placement
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA Stock Earnings: Kala Pharmaceuticals Misses EPS for Q1 2024
KALA stock results show that Kala Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023
KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.